Weller, M., Ellingson, B., Alexander, B., Wen, P., Sulman, E., Colman, H., … Li, W. (2022). P11.65.B GBM AGILE: A global, phase 2/3 adaptive platform trial to evaluate multiple treatment regimens in newly diagnosed and recurrent glioblastoma. In Neuro-Oncology (Vol. 24, pp. ii73–ii73). Oxford University Press (OUP). https://doi.org/10.1093/neuonc/noac174.254

Weller, M., B. Ellingson, B. Alexander, P. Wen, E. Sulman, H. Colman, D. Berry, et al. “P11.65.B GBM AGILE: A global, phase 2/3 adaptive platform trial to evaluate multiple treatment regimens in newly diagnosed and recurrent glioblastoma.” In Neuro-Oncology, 24:ii73–ii73. Oxford University Press (OUP), 2022. https://doi.org/10.1093/neuonc/noac174.254.

Weller M, Ellingson B, Alexander B, Wen P, Sulman E, Colman H, et al. P11.65.B GBM AGILE: A global, phase 2/3 adaptive platform trial to evaluate multiple treatment regimens in newly diagnosed and recurrent glioblastoma. In: Neuro-Oncology. Oxford University Press (OUP); 2022. p. ii73–ii73.

Weller, M., et al. “P11.65.B GBM AGILE: A global, phase 2/3 adaptive platform trial to evaluate multiple treatment regimens in newly diagnosed and recurrent glioblastoma.” Neuro-Oncology, vol. 24, no. Supplement_2, Oxford University Press (OUP), 2022, pp. ii73–ii73. Crossref, doi:10.1093/neuonc/noac174.254.

Weller M, Ellingson B, Alexander B, Wen P, Sulman E, Colman H, Berry D, Tanner K, Khasraw M, Lim M, Perry J, Lassman A, Cloughesy T, Yung WKA, Lee EQ, Mellinghoff I, Gordon G, de Groot J, Mikkelsen T, Cavenee W, Nelli A, Buxton M, Li W. P11.65.B GBM AGILE: A global, phase 2/3 adaptive platform trial to evaluate multiple treatment regimens in newly diagnosed and recurrent glioblastoma. Neuro-Oncology. Oxford University Press (OUP); 2022. p. ii73–ii73.